SN-38
- Generic Name
- SN-38
- Brand Names
- Trodelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20N2O5
- CAS Number
- 86639-52-3
- Unique Ingredient Identifier
- 0H43101T0J
- Background
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...
- Indication
Investigated for use/treatment in colorectal cancer.
- Associated Conditions
- Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma
- Associated Therapies
- -
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 46
- Registration Number
- NCT04863885
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT04826341
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 180
- Registration Number
- NCT04794699
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 331
- Registration Number
- NCT04639986
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04617522
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 1332
- Registration Number
- NCT04595565
- Locations
- 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
🇪🇸Hospital Galdakao-Usansolo, Galdakao, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Spain
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
- Conditions
- Metastatic Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Metastatic Renal Pelvis Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Urothelial CarcinomaStage IV Renal Pelvis and Ureter Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Metastatic Ureter Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT04579224
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Sacituzumab Govitecan in Recurrent Glioblastoma
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 40
- Registration Number
- NCT04559230
- Locations
- 🇺🇸
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 696
- Registration Number
- NCT04527991
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of California Irvine (UCIMC), Orange, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT04468061
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Eastern Maine Medical Center, Brewer, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.